SOUTH SAN FRANCISCO — Poniard Pharmaceuticals Inc. said Monday its cancer drug candidate picoplatin did not help lung cancer patients live longer, sending its shares plunging in early trading. Poniard was running a late-stage trial of picoplatin as a …
Read Original Story: Poniard cancer drug misses goal in lung cancer – The Associated Press
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) today announced that its Pivotal Phase 3 SPEAR trial of Picoplatin did not meet primary endpoints. The trial was conducted with the US Food and Drug Administration (FDA) under a special Protocol Assessment. …
Read Original Story: Poniard Pharmaceuticals Shares Slammed – Benzinga
Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) declines 76.91% to $1.75 on 9.41 million shares after Poniard Pharmaceuticals Inc.’s Picoplatin treatment for small-cell lung cancer didn’t meet its primary overall survival endpoint in a late-stage study of …
Read Original Story: Biggest NASDAQ Losers Today – PARD, CRXX, CHIO – TransWorldNews (press release)
Boston (DbTechNo) – Results of a study featuring an experimental lung cancer drug developed by Poniard are not promising. Shares of the company tanked by 80% upon news of the failed study of the experimental drug, picoplatin. The drug was being tested …
Read Original Story: picoplatin Lung Cancer Drug Flunks Study – dBTechno
Poniard Pharmaceuticals Inc.’s (PARD) picoplatin treatment for small-cell lung cancer didn’t meet its primary overall survival endpoint in a late-stage study of its effectiveness in patients who have relapsed. Shares tumbled 78% premarket to $1.70. …
Read Original Story: Poniard Shares Tumble As Lung Cancer Drug Doesn't Meet Goal – Wall Street Journal
Dashing investors’ hopes, Poniard this morning revealed that its lead drug, the platinum-based cancer drug picoplatin, failed to hit its primary endpoint in a late-stage trial for advanced small cell lung cancer. That’s a bitter disappointment for a …
Read Original Story: BREAKING NEWS: Poniard shares crash on PhIII picoplatin failure – FierceBiotech
(RTTNews) – Monday, Poniard Pharmaceuticals, Inc. (PARD: News ), a biopharmaceutical company, said its pivotal Phase 3 study of Picoplatin efficacy after relapse in the second-line treatment of small cell lung cancer or SCLC did not meet its primary …
Read Original Story: Poniard Pharma's Pivotal Phase 3 Trial Of Picoplatin In SCLC Fails To Meet … – RTT News
SOUTH SAN FRANCISCO, Calif., Nov. 16 /PRNewswire-FirstCall/ — Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of …
Read Original Story: Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial of Picoplatin in … – PR Newswire (press release)
Poniard Pharma announces Ph. 3 SPEAR trial of picoplatin in SCLC did not meet primary endpoint Co announces that its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung …
Read Original Story: Market Report — In Play (PARD) – MSN Money
SOUTH SAN FRANCISCO, Calif. (TheStreet) — Poniard Pharmaceuticals’(PARD Quote) cancer drug picoplatin failed to significantly prolong survival in patients with advanced small cell lung cancer, according to …
Read Original Story: Poniard Cancer Drug Fails Pivotal Study: BioBuzz – TheStreet.com
